ASSOCIATION BETWEEN RESPONSIVENESS TO PHENOBARBITAL INDUCTION OF CYP2B1/2 AND 3A1 IN RAT HEPATIC HYPERPLASTIC NODULES AND THEIR ZONAL ORIGIN

被引:5
|
作者
CHEN, ZY
EATON, DL
机构
关键词
D O I
10.2307/3431866
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
To explore further the mechanism underlying the alteration in expression of P450 enzymes in hepatic preneoplastic lesions, expression of CYP2B1/2 and 3A1 in individual hepatic hyperplastic nodules induced by an aflatoxin B-1 (AFB) administration protocol and the Solt-Farber resistance protocol in male F344 rats was examined via immunohistology. In nodules induced by the resistance protocol, expression of both CYP2B1/2 and 3A1 proteins was highly variable among different nodules, whereas these P450 proteins were expressed in all nodules induced by the AFB protocol. Nodules induced by the resistance protocol have been shown previously to arise from throughout the acinar lobule. In contrast to the resistance protocol, the AFB protocol causes extensive periportal necrosis, potentially resulting in a heavy selection pressure for clonal expansion of initiated cells arising from the centrilobular area. As phenobarbital-induced expression of both CYP2B1/2 and 3A1 in normal liver is heavily localized to the centrilobular zone, these observations suggest that the ability of preneoplastic nodules to respond to induction of these P450 proteins is determined primarily from the zonal origin of the precursor hepatocytes. Thus, the nodules from the resistance protocol that express little or no CYP2B1/2 and 3A1 may have been derived from the periportal hepatocytes, whereas all the nodules in the AFB group and some of the nodules from the resistance protocol which expressed these P450 proteins in response to phenobarbital induction may have been derived from centrilobular hepatocytes.
引用
收藏
页码:185 / 190
页数:6
相关论文
共 50 条
  • [1] Phenobarbital induction of hepatic CYP2B1 and CYP2B2: Pretranscriptional and post-transcriptional effects of gender, adult age, and phenobarbital dose
    Agrawal, AK
    Shapiro, BH
    MOLECULAR PHARMACOLOGY, 1996, 49 (03) : 523 - 531
  • [2] Effect of ovariectomy and androgen on phenobarbital induction of hepatic CYP2B1 and CYP2B2 in Sprague-Dawley rats
    Chang, TKH
    Anderson, MD
    Bandiera, SM
    Bellward, GD
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (08) : 994 - 1000
  • [3] PHENOBARBITAL INDUCTION OF CYP2B1, CYP2B2, AND CYP3A1 IN RAT-LIVER - GENETIC-DIFFERENCES IN A COMMON REGULATORY MECHANISM
    LARSEN, MC
    JEFCOATE, CR
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1995, 321 (02) : 467 - 476
  • [4] INTRACELLULAR CASCADE CONTROLLING THE PHENOBARBITAL-INDUCTION OF THE CYP2B1 GENE IN RAT HEPATOCYTES
    THORNTON, AJ
    JUNE, J
    WEBSTER, S
    GUMUCIO, JJ
    HEPATOLOGY, 1995, 22 (04) : 779 - 779
  • [5] Insulin suppresses the induction of CYP2B1 and CYP2B2 gene expression by phenobarbital in adult rat cultured hepatocytes
    Yoshida, Y
    Kimura, N
    Oda, H
    Kakinuma, A
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 229 (01) : 182 - 188
  • [6] NF-1 and flanking sequences are involved in phenobarbital (PB) induction of CYP2B1/2
    Liu, S
    Park, Y
    Rivera-Rivera, I
    Kemper, B
    FASEB JOURNAL, 1997, 11 (09): : A816 - A816
  • [7] Phosphorylation/dephosphorylation steps are crucial for the induction of CYP2B1 and CYP2B2 gene expression by phenobarbital
    Kawamura, A
    Yoshida, Y
    Kimura, N
    Oda, H
    Kakinuma, A
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 264 (02) : 530 - 536
  • [8] Impaired CYP2B1 induction after hepatic heme depletion
    Han, XM
    Correia, MA
    DRUG METABOLISM REVIEWS, 2003, 35 : 129 - 129
  • [9] Role of constitutive androstane receptor in the in vivo induction of Mrp3 and CYP2B1/2 by phenobarbital
    Xiong, H
    Yoshinari, K
    Brouwer, KLR
    Negishi, M
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (08) : 918 - 923
  • [10] Imprinted overinduction of hepatic CYP2B1 and 2B2 in adult rats neonatally exposed to phenobarbital
    Agrawal, AK
    Shapiro, BH
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 279 (02): : 991 - 999